OBJECTIVES: We aimed to highlight the utility of novel dissolving microneedle (MN)-based delivery systems for enhanced transdermal protein delivery. Vaccination remains the most accepted and effective approach in offering protection from infectious diseases. In recent years, much interest has focused on the possibility of using minimally invasive MN technologies to replace conventional hypodermic vaccine injections. METHODS: The focus of this study was exploitation of dissolving MN array devices fabricated from 20% w/w poly(methyl vinyl ether/maleic acid) using a micromoulding technique, for the facilitated delivery of a model antigen, ovalbumin (OVA). KEY FINDINGS: A series of in-vitro and in-vivo experiments were designed to demonstrate that MN arrays loaded with OVA penetrated the stratum corneum and delivered their payload systemically. The latter was evidenced by the activation of both humoral and cellular inflammatory responses in mice, indicated by the production of immunoglobulins (IgG, IgG1, IgG2a) and inflammatory cytokines, specifically interferon-gamma and interleukin-4. Importantly, the structural integrity of the OVA following incorporation into the MN arrays was maintained. CONCLUSION: While enhanced manufacturing strategies are required to improve delivery efficiency and reduce waste, dissolving MN are a promising candidate for 'reduced-risk' vaccination and protein delivery strategies.
OBJECTIVES: We aimed to highlight the utility of novel dissolving microneedle (MN)-based delivery systems for enhanced transdermal protein delivery. Vaccination remains the most accepted and effective approach in offering protection from infectious diseases. In recent years, much interest has focused on the possibility of using minimally invasive MN technologies to replace conventional hypodermic vaccine injections. METHODS: The focus of this study was exploitation of dissolving MN array devices fabricated from 20% w/w poly(methyl vinyl ether/maleic acid) using a micromoulding technique, for the facilitated delivery of a model antigen, ovalbumin (OVA). KEY FINDINGS: A series of in-vitro and in-vivo experiments were designed to demonstrate that MN arrays loaded with OVA penetrated the stratum corneum and delivered their payload systemically. The latter was evidenced by the activation of both humoral and cellular inflammatory responses in mice, indicated by the production of immunoglobulins (IgG, IgG1, IgG2a) and inflammatory cytokines, specifically interferon-gamma and interleukin-4. Importantly, the structural integrity of the OVA following incorporation into the MN arrays was maintained. CONCLUSION: While enhanced manufacturing strategies are required to improve delivery efficiency and reduce waste, dissolving MN are a promising candidate for 'reduced-risk' vaccination and protein delivery strategies.
Authors: F Beisson; M Aoubala; S Marull; A M Moustacas-Gardies; R Voultoury; R Verger; V Arondel Journal: Anal Biochem Date: 2001-03 Impact factor: 3.365
Authors: Juliana De Souza Rebouças; Juan Manuel Irache; Ana I Camacho; Irene Esparza; Victoria Del Pozo; María L Sanz; Marta Ferrer; Carlos Gamazo Journal: Eur J Pharm Biopharm Date: 2012-07-08 Impact factor: 5.571
Authors: Ryan F Donnelly; Rita Majithiya; Thakur Raghu Raj Singh; Desmond I J Morrow; Martin J Garland; Yusuf K Demir; Katarzyna Migalska; Elizabeth Ryan; David Gillen; Christopher J Scott; A David Woolfson Journal: Pharm Res Date: 2010-05-19 Impact factor: 4.200
Authors: Wenchao Sun; Zeynep Araci; Mohammed Inayathullah; Sathish Manickam; Xuexiang Zhang; Marc A Bruce; M Peter Marinkovich; Alfred T Lane; Carlos Milla; Jayakumar Rajadas; Manish J Butte Journal: Acta Biomater Date: 2013-05-03 Impact factor: 8.947
Authors: Ryan F Donnelly; Desmond I J Morrow; Thakur R R Singh; Katarzyna Migalska; Paul A McCarron; Conor O'Mahony; A David Woolfson Journal: Drug Dev Ind Pharm Date: 2009-10 Impact factor: 3.225
Authors: Maelíosa T C McCrudden; Ahlam Zaid Alkilani; Aaron J Courtenay; Cian M McCrudden; Bronagh McCloskey; Christine Walker; Nida Alshraiedeh; Rebecca E M Lutton; Brendan F Gilmore; A David Woolfson; Ryan F Donnelly Journal: Drug Deliv Transl Res Date: 2015-02 Impact factor: 4.617
Authors: Stephen C Balmert; Cara Donahue Carey; Gabriel D Falo; Shiv K Sethi; Geza Erdos; Emrullah Korkmaz; Louis D Falo Journal: J Control Release Date: 2019-11-19 Impact factor: 9.776
Authors: Emrullah Korkmaz; Stephen C Balmert; Cara Donahue Carey; Geza Erdos; Louis D Falo Journal: Expert Opin Drug Deliv Date: 2020-10-06 Impact factor: 8.129
Authors: Ryan F Donnelly; Maelíosa T C McCrudden; Ahlam Zaid Alkilani; Eneko Larrañeta; Emma McAlister; Aaron J Courtenay; Mary-Carmel Kearney; Thakur Raghu Raj Singh; Helen O McCarthy; Victoria L Kett; Ester Caffarel-Salvador; Sharifa Al-Zahrani; A David Woolfson Journal: PLoS One Date: 2014-10-31 Impact factor: 3.240
Authors: Patricia González-Vázquez; Eneko Larrañeta; Maelíosa T C McCrudden; Courtney Jarrahian; Annie Rein-Weston; Manjari Quintanar-Solares; Darin Zehrung; Helen McCarthy; Aaron J Courtenay; Ryan F Donnelly Journal: J Control Release Date: 2017-07-25 Impact factor: 9.776
Authors: Aoife M Rodgers; Maelíosa T C McCrudden; Aaron J Courtenay; Mary-Carmel Kearney; Katherine L Edwards; Rebecca J Ingram; Jose Bengoechea; Ryan F Donnelly Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Kai Jun Koh; Yi Liu; Seng Han Lim; Xian Jun Loh; Lifeng Kang; Chee Yen Lim; Kyle K L Phua Journal: Sci Rep Date: 2018-08-07 Impact factor: 4.379
Authors: Aoife M Rodgers; Maelíosa T C McCrudden; Eva M Vincente-Perez; Alice V Dubois; Rebecca J Ingram; Eneko Larrañeta; Adrien Kissenpfennig; Ryan F Donnelly Journal: Int J Pharm Date: 2018-07-23 Impact factor: 5.875